Stephen Gordon sold $1.3M of TMDX
Chief Financial Officer at TransMedics Group, Inc.. 15,000 shares at an average of $85.45, traded Feb 1, 2024, filed Feb 2, 2024.
Score components
- +22RoleCFO
- +25Trade size$1.3M at market
- +20Share of holdings soldSold 53% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.2%, 3m +45.1%, 6m +70.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-010796, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 1, 2024 | MOption exercise Common Stock10b5-1 | +8,833 | $13.28 | $117k | 21,908 | Feb 2, 2024 |
| Feb 1, 2024 | MOption exercise Common Stock10b5-1 | +3,644 | $16.14 | $59k | 25,552 | Feb 2, 2024 |
| Feb 1, 2024 | MOption exercise Common Stock10b5-1 | +2,523 | $38.46 | $97k | 28,075 | Feb 2, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -15,000 | $85.45 | $1.3M | 13,075 | Feb 2, 2024 |
| Feb 1, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,833 | $0.00 | $0 | 28,167 | Feb 2, 2024 |
| Feb 1, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,644 | $0.00 | $0 | 2,084 | Feb 2, 2024 |
| Feb 1, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,523 | $0.00 | $0 | 67,477 | Feb 2, 2024 |
Related signals
Other insiders at TransMedics Group, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | TMDXbuy TransMedics Group, Inc. | David Weill director | $109k 1,336 shares | +9% | |
| 31Weak | TMDXsell TransMedics Group, Inc. | Thomas James Gunderson director | $722k 9,624 shares | -37% | |
| 52Moderate | TransMedics Group, Inc. | Stephanie Lovell director | $178k 1,193 shares | -29% | |
| 38Weak | TransMedics Group, Inc. | David Weill director | $524k 3,571 shares | -23% | |
| 46Moderate | TransMedics Group, Inc. | Nicholas Corcoran See remarks | $413k 2,966 shares | -9% | |
| 67Notable | TransMedics Group, Inc. | Gerardo Hernandez Chief Financial Officer | $1.1M 7,611 shares | -51% | |
| 40Moderate | TransMedics Group, Inc. | Anil P. Ranganath See remarks | $120k 864 shares | -6% | |
| 48Moderate | TransMedics Group, Inc. | Gerardo Hernandez Chief Financial Officer | $128k 920 shares | -6% | |
| 46Moderate | TransMedics Group, Inc. | David Weill director | $693k 5,000 shares | -29% | |
| 37Weak | TransMedics Group, Inc. | Anil P. Ranganath See remarks | $436k 3,000 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.